Document is current
Any future updates will be listed below
-
Authors
Xie, Ping
Huang, Yuanfang
Wang, Yongsheng
Shi, Huashan
Chen, Yan
Gou, Zehui
Lai, Ling
Dang, Qi
Wu, Xian
Yang, Sheng-Tao
Tang, Xiaohai
-
Funding
Funding for this research was provided by:
Science and Technology Department of Sichuan Province (2024YFFK0014)
- License Information
-
More Information
Article History
Received: 20 March 2026
Accepted: 18 May 2026
First Online: 5 June 2026
Declarations
:
: The trial was approved by the ethics committees of all three participating centers: the Ethics Committee on Clinical Trial of West China Hospital of Sichuan University (Approval No.: 2022 Clinical Trial (Western Medicine) Review No. 238), the Ethics Committee of Shandong First Medical University Affiliated Tumor Hospital (Approval No.: SDZLEC2023-203-01), and the Clinical Research Ethics Committee of the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (Approval No.: 2023-003-01). All procedures complied with the Declaration of Helsinki. The written informed consent was obtained from all participants prior to enrollment.
: The consent form was signed by the patients. All authors approved the manuscript for submission.
: Ping Xie, Yuanfang Huang, Yan Chen and Xiaohai Tang are employees of Sichuan Enray Pharmaceutical Sciences Company, the developer of CNSI-Fe. This study was supported in part by the company. The authors declare that they have no other competing interests.
